Neukio Biotherapeuticsa Chinese company engaged in the development of cell therapy products, raised $50 million in Series A-1 funding.
The round was led by CD Capital, with participation from Alwin Capital, Surplus Capital, Lilly Asia Ventures, Sherpa Healthcare Partners and IDG Capital.
The company, founded at Simbay Park in the Shanghai Pilot Free Trade Zone (China) in June 2021, intends to use the funds to accelerate preclinical and clinical validation of induced pluripotent stem cells (iPSCs). NK Cell Therapy Products and Support Team Recruitment and Expansion.
Led by CEO, Dr. Richard Liqun Wang, Neukio Biotherapeutics is a biotherapeutics company focused on the development and commercialization of immune cell therapy. Its management team has established a pipeline development strategy based on iPSC-CAR-NK, aiming to launch ready-to-use allogeneic cell therapy products that can be produced at scale for the treatment of solid tumors. The company is both focused on in-house R&D to provide valuable clinical solutions to cancer patients worldwide.
Since its inception just over a year ago, Neukio has made remarkable progress in recruiting talent, building facilities, advancing the R&D pipeline, and establishing a management system. quality, exceeding all expectations.